Entrada Therapeutics, Inc.
Entrada Therapeutics, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is Next quarterly earnings (projected) on December 23, 2026, a projected date rather than a confirmed one. There are 4 upcoming events on record.
Cash runway is approximately 7.1 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
| Date | Event | Type | Phase |
|---|---|---|---|
| December 23, 2026 est. | Next quarterly earnings (projected) | Earnings | — |
| March 1, 2029 | A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping to Evaluate the Safety and Efficacy of ENTR-601-45 | Trial Milestone | Phase 1/Phase 2 |
| March 28, 2029 | A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping to Evaluate the Safety and Efficacy of ENTR-601-44 | Trial Milestone | Phase 1/Phase 2 |
| March 15, 2032 | Long-Term Extension Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon Skipping to Evaluate the Safety and Efficacy of Endosomal Escape Vehicle Phosphorodiamidate Morpholino Oligomer Platform Products (ELEVATE-LTE) | Trial Milestone | Phase 2 |
Track TRDA alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open TRDA in the tracker| Date | Event | Type | Phase |
|---|---|---|---|
| October 14, 2026 | 8-K filed: Reg FD disclosure, Other event | Filing | — |
| August 5, 2026 | Quarterly results filed (8-K) | Earnings | — |
| June 10, 2026 | 8-K filed: Leadership change | Corporate | — |
| May 19, 2026 | 8-K filed: Reg FD disclosure | Filing | — |
| May 7, 2026 | Quarterly results filed (8-K) | Earnings | — |
| February 26, 2026 | Quarterly results filed (8-K) | Earnings | — |
| January 8, 2026 | Quarterly results filed (8-K) | Earnings | — |
| November 6, 2025 | Quarterly results filed (8-K) | Earnings | — |
| August 6, 2025 | Quarterly results filed (8-K) | Earnings | — |
| June 3, 2025 | 8-K filed: Leadership change, Reg FD disclosure | Corporate | — |
| May 8, 2025 | Quarterly results filed (8-K) | Earnings | — |
Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.